KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) Income towards Parent Company (2016 - 2025)

Globus Medical (GMED) has disclosed Income towards Parent Company for 15 consecutive years, with $140.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income towards Parent Company rose 430.44% year-over-year to $140.6 million, compared with a TTM value of $537.9 million through Dec 2025, up 422.28%, and an annual FY2025 reading of $537.9 million, up 422.28% over the prior year.
  • Income towards Parent Company was $140.6 million for Q4 2025 at Globus Medical, up from $119.0 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $202.8 million in Q2 2025 and bottomed at -$197.2 million in Q4 2022.
  • Average Income towards Parent Company over 5 years is $42.8 million, with a median of $46.3 million recorded in 2021.
  • The sharpest move saw Income towards Parent Company tumbled 1405.41% in 2022, then skyrocketed 5088.79% in 2024.
  • Year by year, Income towards Parent Company stood at $15.1 million in 2021, then crashed by 1405.41% to -$197.2 million in 2022, then soared by 107.62% to $15.0 million in 2023, then surged by 76.3% to $26.5 million in 2024, then surged by 430.44% to $140.6 million in 2025.
  • Business Quant data shows Income towards Parent Company for GMED at $140.6 million in Q4 2025, $119.0 million in Q3 2025, and $202.8 million in Q2 2025.